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Brown fat organogenesis and maintenance
requires AKT1 and AKT2
Joan Sanchez-Gurmaches 1,4,5,*, Camila Martinez Calejman 1, Su Myung Jung 1, Huawei Li 1,
David A. Guertin 1,2,3,**
ABSTRACT
Objective: Understanding the signaling mechanisms that control brown adipose tissue (BAT) development is relevant to understanding energy
homeostasis and obesity. The AKT kinases are insulin effectors with critical in vivo functions in adipocytes; however, their role in adipocyte
development remains poorly understood. The goal of this study was to investigate AKT function in BAT development.
Methods: We conditionally deleted Akt1 and Akt2 either individually or together with Myf5-Cre, which targets early mesenchymal precursors that
give rise to brown adipocytes. Because Myf5-Cre also targets skeletal muscle and some white adipocyte lineages, comparisons were made
between AKT function in BAT versus white adipose tissue (WAT) and muscle development. We also deleted both Akt1 and Akt2 in mature brown
adipocytes with Ucp1-Cre or Ucp1-CreER to investigate AKT1/2 signaling in BAT maintenance.
Results: AKT1 and AKT2 are individually dispensable in Myf5-Cre lineages in vivo for establishing brown and white adipocyte precursor cell
pools and for their ability to differentiate (i.e. induce PPARg). AKT1 and AKT2 are also dispensable for skeletal muscle development, and AKT3
does not compensate in either the adipocyte or muscle lineages. In contrast, AKT2 is required for adipocyte lipid ﬁlling and efﬁcient downstream
AKT substrate phosphorylation. Mice in which both Akt1 and Akt2 are deleted with Myf5-Cre lack BAT but have normal muscle mass, and doubly
deleting Akt1 and Akt2 in mature brown adipocytes, either congenitally (with Ucp1-Cre), or inducibly in older mice (with Ucp1-CreER), also ablates
BAT. Mechanistically, AKT signaling promotes adipogenesis in part by stimulating ChREBP activity.
Conclusions: AKT signaling is required in vivo for BAT development but dispensable for skeletal muscle development. AKT1 and AKT2 have both
overlapping and distinct functions in BAT development with AKT2 being the most critical individual isoform. AKT1 and AKT2 also have distinct and
complementary functions in BAT maintenance.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. INTRODUCTION
Adipose tissue maintains systemic metabolic homeostasis through
metabolic and endocrine pathways. In obesity or lipodystrophy,
dysfunctional adipose tissue causes insulin resistance, type 2 diabetes,
and many other serious comorbidities [1,2]. In overweight or obesity,
white adipose tissue (WAT) distribution of subcutaneous versus visceral
fat, rather than total fat, is often a stronger predictor of associated
comorbidities [3e6]. Moreover, increased brown adipose tissue (BAT)
abundance is associated with improved metabolic ﬁtness and strategies
to increase BAT amount and/or function are being considered as ther-
apeutic strategies to ﬁght metabolic diseases [3e15]. Thus, under-
standing BAT development is of high clinical relevance.
Lineage tracing in mice has revealed that adipose tissue development
is complex, and the emerging view is that adipocytes are heteroge-
neous both developmentally and functionally [16,17]. For example,
early mesenchymal precursor cells expressing Myf5 (i.e. marked with
Myf5-Cre) give rise to the brown adipocytes in the interscapular and
subscapular BAT, or iBAT and sBAT, respectively, but to only about half
of the brown adipocytes in the cervical BAT depot, and to no brown
adipocytes in the peri-renal or peri-aortic BAT depots. Some WAT
depots (e.g. the anterior-subcutaneous (asWAT) and retroperitoneal
WAT (rWAT), but not posterior subcutaneous (psWAT), mesenteric, or
peri-gonadal WAT (pgWAT) depots) also contain many Myf5-Cre line-
age adipocytes, as do skeletal muscles and their associated satellite
cells [18e23]. Other studies have identiﬁed Wt1 and Prrx1 as markers
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of different precursor pools that heterogeneously give rise to adipo-
cytes in other depots [24e26]. Notably, Cre-mediated recombination
can be exploited in these multi-potential lineages to distinguish
pathways speciﬁcally required for adipocyte development.
Genetic studies using Myf5-Cre highlight the role of insulin signaling in
establishing and distributing adipose tissue. For example, deleting
insulin receptor beta with Myf5-Cre (IRmyf5cKO) does not affect total
body weight or muscle mass but results in selective lipodystrophy of
the dorsal-anterior BAT and WAT depots with corresponding hyper-
trophy of the ventral-posterior WAT depots [18,21]. The regionalized
lipodystrophy in IRmyf5cKO mice is not due to a defect in establishing
adipocyte precursor cells, for which IRb is dispensable but rather to
IRb0s critical role in lipid ﬁlling of the adipocytes. In contrast, deleting
Pten with Myf5-Cre (PTENmyf5cKO), which encodes the major negative
regulator of PI3-kinase, redistributes body fat in the opposite direction,
resulting in hypertrophy of dorsal-anterior BAT and WAT depots and
the complete disappearance of all Myf5-Cre lineage negative fat depots
[19]. In this model, Pten loss also expands the Myf5þ precursor cell
population. Interestingly, PTENmyf5cKO mice additionally have partial
muscle atrophy and phenotypically resemble humans that suffer from
a rare and devastating body fat distribution disorder called Multiple
Symmetric Lipomatosis or Madelung’s disease [27]. These ﬁndings
suggest that biochemical differences in insulin signaling or metabolism
between adipocyte lineages can determine body fat patterning.
The mechanistic Target of Rapamycin (mTOR) is a major intracellular
effector of insulin and has also been studied genetically with Myf5-Cre.
The functions of mTOR are split between two complexes called mTOR
complex 1 (mTORC1) and mTORC2 [28,29]. mTORC1 contains the
essential Raptor subunit and phosphorylates the AGC-family kinase
S6K and several non-AGC family substrates to promote anabolic
growth. mTORC2 uniquely contains the essential Rictor subunit,
phosphorylates the AGC-family kinases AKT and SGK, and regulates
glucose and lipid metabolism; however, its downstream mechanisms
of action remain more elusive [28,30e35]. Consistent with mTORC1’s
broad role in anabolic metabolism, Myf5-cre;Raptor mice (Raptor-
myf5cKO) die in late embryonic development with severe muscle and
BAT development defects [30]. In contrast, Myf5-cre;Rictor mice
(Rictormyf5cKO) are viable, have no obvious defects in muscle devel-
opment or repair, but have severe localized lipoatrophy similar to
IRmyf5cKO mice [18,30]. Moreover, while mTORC2-dependent AKT
phosphorylation is ablated in in the BAT of Rictormyf5cKO mice, many
AKT substrates are still phosphorylated normally. Thus, mTORC2 is
uniquely essential in the Myf5-Cre lineage for adipose tissue growth,
but its mechanism of action remains to be elucidated.
AKT (also known as PKB) mediates many aspects of cell growth,
metabolism, and survival downstream of insulin signaling [36]. The AKT
kinase family comprises three isoforms expressed from different genes,
called AKT1, AKT2, and AKT3 (or PKBa, PKBb, and PKBg). mTORC2
phosphorylates the AKT hydrophobic motif site (HM; S473 in AKT1,
S474 in AKT2, and S472 in AKT3), which is required for full activation
[28,31]. However, as in Rictormyf5cKO mice, several studies show that
AKT HM phosphorylation is not essential for many AKT signaling events
[30,32,37e39]. This is likely due in part to the fact that PDK1 can
phosphorylate AKT in the T-loop kinase domain motif (T308 in AKT1;
T309 in AKT2; T305 in AKT3) independently of HM phosphorylation
[40e42], and is sufﬁcient for many AKT functions. Thus, the exact
in vivo function of mTORC2 in AKT signaling has not been fully resolved.
Here, we investigate the role of the AKT isoforms in BAT and muscle
development by combining Akt1 and/or Akt2 ﬂoxed alleles with Myf5-
Cre with or without whole body Akt3 deletion. Although previous
studies modeling adipogenesis in vitro suggest an essential role for AKT1
[30,43,44], AKT1 is dispensable in vivo in the Myf5-lineage for adipose
tissue development, and AKT3 does not compensate. In contrast, AKT2
is essential for adipose tissue growth, not because it controls differen-
tiation per se, but because it promotes lipid accumulation, and its loss
results in body fat redistribution. We additionally ﬁnd that deleting both
Akt1 and Akt2, either in precursors or mature brown adipocytes, causes
severe BAT lipodystrophy without having any obvious effect on muscle
development. These ﬁndings contribute signiﬁcantly to understanding
the complex relationship between the AKT isoforms and their regulators
in adipose tissue development and maintenance.
2. MATERIAL AND METHODS
2.1. Mice and mice housing
Akt1 and Akt2 ﬂoxed mice and Akt3 knockout mice were generously
provided by Morrie Birnbaum (UPenn, Pﬁzer). Other lines are described
elsewhere; R26R-mTmG mice (JAX stock 007676); Myf5-Cre mice
(JAX stock 007893); Ucp1-CreERT2 mice [45]; UCP1-Cre (JAX stock
024670). The control mice used in each set of experiments are indi-
cated in the appropriate ﬁgures legends. All mice were on the C57BL/
6J background. Mice were housed in the Animal Medicine facilities of
UMMS in a room set at 22 C and 45% humidity under daily 12h light/
dark cycles. All animals were sacriﬁced in the morning and fed ad
libitum unless otherwise noted in the ﬁgure legends. For fasting and
refeeding experiments, the food (standard chow diet) was deprived
starting at 6e7 pm until the next morning at 9 am. At that time, a
subgroup of mice was given chow and allowed to feed ad libitum for
45 min prior to tissue harvest. All procedures were approved by the
University of Massachusetts Medical School Institutional Animal Care
and Use Committee.
2.2. Cell culture
The cell lines used here are described in [46]. Brieﬂy, brown pre-
adipocytes were isolated from Ubc-CreERT2;Akt1ﬂoxedAkt2ﬂoxed P1 neo-
nates and immortalized with pBabe-SV40 Large T. The gender of the
neonates was not determined. Cells were maintained in high-glucose
DMEM medium in incubators at 37 C and 5% CO2. Cells stably
expressing recombinant proteins were obtained by using lentiviral sys-
tems. Deletion of the Akt1 and Akt2 genes was obtained by treating the
cells with one dose of 4-hydroxytamoxifen (4-OHT, 1 mM) 4 days before
seeding them for differentiation assays. Control cells received equivalent
dose of vehicle (ethanol). Cell were allowed to differentiate for 12 days
[46]. Brieﬂy, cells were seeded at medium density and allowed to
proliferate to conﬂuence in the presence of high-glucose DMEM medium
supplemented with 10% FBS, 1% antibiotics, 20 nM insulin, and 1 nM
T3. After 4 days, the cells were induced to differentiate by adding in-
duction media (high-glucose DMEM with 10% FBS, 1% antibiotics,
20 nM insulin, 1 nM T3, 0.125 mM indomethacin, 2 mg/mL dexa-
methasone and 0.5 mM 3-isobutyl-1-methylxanthine (IBMX)) for 2 days.
Subsequently, the medium (high-glucose DMEM, 10% FBS,1% antibi-
otics) with insulin and T3 was changed every 2 days until day 12. For
C75 inhibitor treatment, C75 was added to the appropriate concentration
in the media starting at day 6 of differentiation and changed every other
day while the controls received the equivalent dose of vehicle (DMSO).
Fresh media was added to the cells one hour before harvest.
2.3. In vivo tamoxifen treatment
6-week-old mice were treated I.P. with 100uL/day/mouse of Tamoxifen
(at 20 mg/mL in corn oil/ethanol (9:1 vol/vol)) for 5 times in a period of
seven days. Mice treated with tamoxifen and fed standard chow ad
libitum were sacriﬁced one or three weeks post tamoxifen treatment in
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the morning. Note that tamoxifen treatment in vivo has been reported to
cause temporary lipoatrophy and induce browning [47e49]. In control
mice treated I.P. with tamoxifen, we did not observe any differences in
total body weight or individual fat depot weights one week after the ﬁrst
tamoxifen treatment (two days after the last) compared to age/gender/
strain matched mice treated with vehicle.
2.4. Tissue histology
Tissue pieces were ﬁxed in 10% formalin. Embedding, sectioning and
Hematoxylin and Eosin (H&E) staining was done by the UMMS
Morphological Core facility.
2.5. Gene expression and western blot analysis
Total isolated RNA (Qiazol and RNeasy kit (Qiagen)), was used for ret-
rotranscription (High Capacity cDNA reverse transcription kit (#4368813,
Applied Biosystems)) and analyzed by qPCR (StepOnePlus real-time PCR
machine, Applied Biosystems) using speciﬁc primers. Primer sequences
are shown in Supplementary Table 1. Counts per million (cpm) of Akt
isoforms in BAT were obtained from our previously published dataset
GEO: GSE96681. For western blot analysis, protein lysates (typically
10 mg per lane) were run in SDS acrylamide/bis-acrylamide gels
(typically 10%), transferred to PVDF membranes, and detected with
speciﬁc antibodies as speciﬁed in Supplementary Table 2.
2.6. Adipocyte precursor cell (APC) isolation and FACS analysis
Precursor isolation is described in [18]. Brieﬂy, stromal-vascular
fraction (SVF) was prepared from each fat pad by collagenase treat-
ment. Cells were then pelleted by centrifugation, cleared, and sus-
pended in staining media (HBSS þ 2% FBS), and labeled with
appropriate antibodies (Supplementary Table 2). After staining, cells
were ﬁltered through a 35-mm cell-strainer capped tube to ensure
single cell suspension and stained with live/dead Blue. Live single cells
were gated according to the expression of surface markers (CD31-
CD45-CD29 þ CD34 þ Sca1þ) in a BD LSRII analyser. Data were
analyzed with FlowJo.
2.7. Whole mount confocal microscopy
Whole mount confocal microscopy is described in [18]. Brieﬂy, small
pieces of adipose tissues were mounted with Fluoromount-G (Southern
Biotech) and imaged in a LSM 5 Pa (Zeiss) point scanner confocal
system using a 40 oil immersion objective. eGFP was excited at
488 nm and detected from 515 to 565 nm tdTomato was excited at
543 nm and detected from 575 to 640 nm. Images were processed in
Adobe Phostoshop and ImageJ.
2.8. Statistical analysis
Data are presented as mean þ s.e.m., unless stated otherwise. Stu-
dent t-test or analysis of variance (one or two ways, follow by Tukey
posthoc analysis), as appropriate, were used to determine statistical
signiﬁcance, which is indicated in each ﬁgure legend. P-values are
indicated as follows: *, p-value<0.005, **, p-value<0.01 and ***, p-
value>0.001. No pre-test was used to choose sample size. Statistical
analysis was done using GraphPad Prism. The number of mice used
per experiment is stated in each ﬁgure legend.
3. RESULTS
3.1. Deleting Akt2, but not Akt1, with Myf5-Cre redistributes body
fat
To investigate the in vivo role AKT1 and AKT2 in Myf5-Creþ cells and
their descendants, we crossed the Myf5-Cre knock-in driver with Akt1
or Akt2 ﬂoxed mice to generate Akt1myf5cKO and Akt2myf5cKO condi-
tional knockout mice. Total body mass is unaffected in both models
(Figure 1A,B). Individual fat and lean tissues were analyzed at 6 weeks
of age as done previously for IRmyf5cKO, PTENmyf5cKO and Rictormyf5cKO
mice [18,19,30]. Akt1myf5cKO mice have normal brown and white ad-
ipose tissue mass when normalized to total body weight (Figure 1A), or
when expressed as total BAT weight (Figure S1A). All other tissues
examined were normal sized except the kidneys, which were slightly
enlarged when normalized to total body weight (Figure S1A, S2A). This
indicates that Akt1 is dispensable in the Myf5-Cre lineage for adipose
tissue and muscle growth.
In contrast to the Akt1myf5cKO mice, Akt2myf5cKO mice exhibit signiﬁcant
changes in body fat distribution. In particular, Akt2myf5cKO mice show
signiﬁcant lipoatrophy of iBAT and sBAT, which are almost completely
derived from Myf5-Creþ precursors (Figure 1B, Figure S1B) [18]. The
cBAT is also decreased but to a lesser degree consistent with only
about 50% of the brown adipocytes in this depot descending from
Myf5-Creþ precursors (Figure 1B, Figure S1B) [18]. The retroperitoneal
WAT (rWAT) of Akt2myf5cKO mice, which is nearly completely derived
from Myf5-Cre lineage precursors, also exhibits signiﬁcant lipoatrophy
(Figure 1B, Figure S1B). In contrast, the Myf5-Cre lineageneg posterior
subcutaneous and peri-gonadal WAT depots (psWAT and pgWAT,
respectively) increase in mass (Figure 1B, Figure S1B) suggesting
compensatory expansion by these Cre-negative (i.e. Akt2 wild type)
adipocytes. The asWAT, which is only partially derived from Myf5-Cre
lineage precursors, shows no differences in mass (Figure 1B,
Figure S1B), which is likely due to compensatory expansion of the
Myf5-Cre negative asWAT fraction as was previously observed in
IRmyf5cKO mice [18]. No other tissues examined including skeletal
muscles (i.e. quadriceps, gastrocnemius and triceps) show any dif-
ferences in mass in the Akt2myf5cKO mice (Figure S1B, S2B). This in-
dicates that Akt2 is required in the Myf5-Cre lineage for normal brown
and white adipose tissue growth but not for skeletal muscle growth.
3.2. AKT2 regulates adipocyte cell size
Adipocyte morphology was next examined by histology. There is no
size difference between control and Akt1myf5cKO brown or white adi-
pocytes in any depot examined. In contrast, Akt2myf5cKO brown adi-
pocytes have reduced lipid content consistent with their small BAT
mass (Figure 1C). In Myf5-Cre lineage rWAT, deleting Akt2 causes the
formation of two morphologically distinct populations of adipocytes;
one that is very small in size and another that is similar in size or larger
than control adipocytes (Figure 1C). Moreover, the increase in psWAT
and pgWAT total mass observed in Akt2myf5cKO mice associates with
adipocyte hypertrophy in these depots (Figure 1C). Thus, adipocyte
lineages deleted for Akt2 generate smaller adipocytes resulting in
tissue atrophy, while the non-targeted lineages give rise to larger
adipocytes resulting in oversized depots.
The heterogeneous mix of small and large adipocytes observed in the
rWAT of Akt2myf5cKO mice is reminiscent of previous results obtained in
the rWAT of IRmyf5cKO and Rictormyf5cKOmice [18,30]. In thesemodels, the
larger adipocytes resulted from the compensatory expansion of Myf5-Cre
lineage negative adipocytes. To test if this is also the case in the Akt2-
myf5cKOmice and to examine how Akt loss affects lineage distribution, we
incorporated the membrane-targeted Tomato ﬂuorescent protein (mTFP)
- membrane targeted green ﬂuorescent protein (mGFP) dual ﬂuorescent
(or mTmG) reporter into both the Akt1myf5cKO and Akt2myf5cKO models
generating Akt1myf5cKO;R26R-mTmG and Akt2myf5cKO;R26R-mTmG
mice. In mice carrying the mTmG reporter, Cre recombinase induces the
expression of mGFP in all Cre expressing cells and their descendants,
while all Cre-negative cells express mTFP [18,50].
Original Article
62 MOLECULAR METABOLISM 23 (2019) 60e74  2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
Using confocal imaging, we ﬁnd no difference in labeling between
control (myf5-Cre;R26R-mTmG) and Akt1myf5cKO;R26R-mTmG mice.
That is, all iBAT and rWAT adipocytes are mGFPþ, indicating Cre
targeting, while all psWAT and pgWAT adipocytes are mTFPþ
(Figure 2A). In contrast, imaging of the Akt2myf5cKO;R26R-mTmG mice
conﬁrms that all brown adipocytes are mGFPþ, consistent with their
uniformly small size, and there is no compensation from Cre-negative
(mTFPþ) lineages (Figure 2A). Moreover, all of the small adipocytes in
the rWAT of Akt2myf5cKO;R26R-mTmG mice are also mGFPþ and
contain multi-locular lipid droplets, while all of the large adipocytes are
mTFPþ, also consistent with previous studies (Figure 2A) [18,30].
Thus, while most early rWAT adipocytes normally originate from Myf5-
Cre marked precursors, Myf5-Cre negative precursors can partially
compensate when the Myf5-Creþ lineage is compromised. Quantiﬁ-
cation of adipocyte size based on lineage shows that the Crenegative
adipocytes in Akt2myf5cKO;R26R-mTmG rWAT of (i.e. mTFPþ) are the
same size as Myf5-lineage adipocytes in both the control mice (myf5-
Cre;R26R-mTmG) and the Akt1myf5cKO;R26R-mTmG mice, while the
Akt2-deleted adipocytes in the Akt2myf5cKO;R26R-mTmG mice (which
are mGFPþ) are signiﬁcantly smaller (Figure S3A). As expected, the
adipocytes in the psWAT and pgWAT of Akt2myf5cKO;R26R-mTmG mice
are uniformly mTFPþ (Myf5-Cre lineage negative). These data indicate
that AKT2 regulates the size of Myf5-Cre lineage brown and white
adipocytes.
Figure 1: Deleting Akt2, but not Akt1, with Myf5-Cre redistributes body fat. (A) Body weight and fat weights of Akt1myf5cKO and littermate controls (Akt1 ﬂoxed) at 6 weeks old
(n ¼ 6, t-test). (B) Body weight and fat weights of Akt2myf5cKO and littermate controls (Akt2 ﬂoxed) at 6 weeks old (n ¼ 11, t-test). (C) Representative H&E images of the indicated
fat depots of Akt1myf5cKO, Akt2myf5cKO and respective control littermates (Akt1 ﬂoxed and Akt2 ﬂoxed, respectively) at 6 weeks old (n ¼ 4).
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3.3. AKT2 is required for adipocyte lipid ﬁlling
Myf5-cre targets early in development in mesenchymal precursor cells
that are not yet committed to becoming adipocytes. Thus, the small
adipocyte and tissue mass phenotype caused by deleting akt2 could be
linked to defects in establishing adipocyte precursor pools, or alter-
natively, to their ability to differentiate. On the other hand, we recently
showed that both Akt2Ucp1CreER and Akt2AdipoqCre mice, in which akt2 is
deleted late in differentiation, also have a small brown and white
adipocytes, respectively, that correspond with decreased overall tissue
size [46]. Thus, the size phenotype could alternatively be caused by a
lipid ﬁlling or storage defect. To distinguish between these possibil-
ities, we next asked whether deleting Akt2 affects establishment of
Myf5-lineage adipocyte precursor pools. Myf5-Cre heterogeneously
marks adipocyte precursors in the stromal vascular fractions (SVFs) of
all major fat depots but must abundantly in the dorsal-anterior depots
(e.g. iBAT, asWAT, and rWAT) [18,23]. Using ﬂuorescence activated
cell sorting with well-established cell surface markers that enrich for
adipocyte precursor cells (APC) [51], we ﬁnd no difference in Myf5-Cre
lineage contribution to the APC pool in either Akt1myf5cKO;R26R-mTmG
mice or of Akt2myf5cKO;R26R-mTmGmice (Figure 2B). The total number
of cells analyzed is shown in Figure 3B. Thus, AKT2 is not required in
the Myf5-lineage to establish normal precursor pools.
We also analyzed several adipocyte differentiation markers. We ﬁnd no
differences in pparg1, c/ebpa, c/ebpb, c/ebpd, pgc1a, or ucp1
expression in Akt1myf5cKO or Akt2myf5cKO BAT, slight increases in
pparg2 and sgk2, and a slight decrease in cidea expression, but only
in Akt2myf5cKO BAT (Figure 2C). No differences were found in the white
fat markers dpt and retn (Figure 2C). In contrast, only Akt2myf5cKO BAT
and not Akt1myf5cKO BAT show dramatic (>90%) reduction acly, acaca,
and fasn expression, which encode regulators of de novo lipogenesis
(Figure 2C). Thus, the small cell size and tissue mass phenotype in
Akt2myf5cKO BAT is not caused by an inability to express differentiation
and/or identity markers, but could relate at least in part to a lipid
synthesis defect.
Figure 2: Akt2 is required for brown adipocyte lipid ﬁlling, but not for differentiation. (A) Representative images of whole-mount preparations of the indicated fat depots of 6
weeks old myf5-Cre; R26R-mTmG, Akt1myf5cKO;R26R-mTmG and Akt2myf5cKO;R26R-mTmG mice (n ¼ 3 for myf5-Cre; R26R-mTmG, 2 for Akt1myf5cKO;R26R-mTmG and 4 for
Akt2myf5cKO;R26R-mTmG). (B) Average percentage of mTFPþ (Red) and mGFPþ (Green) APCs isolated from the indicated depots from 6 weeks old myf5-Cre; R26R-mTmG,
Akt1myf5cKO;R26R-mTmG and Akt2myf5cKO;R26R-mTmG mice (n ¼ 3 for myf5-Cre; R26R-mTmG, 2 for Akt1myf5cKO;R26R-mTmG and 4 for Akt2myf5cKO;R26R-mTmG; no statisti-
cal analysis was used). (C) qPCR analysis of the iBAT of Akt1myf5cKO, Akt2myf5cKO and respective control littermates (Akt1 ﬂoxed and Akt2 ﬂoxed, respectively) at 6 weeks old (n ¼ 6
for Akt1 ﬂoxed and Akt1myf5cKO and n ¼ 8 for Akt2 ﬂoxed and Akt2myf5cKO; t-test).
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Collectively, these data support a model in which AKT1 and AKT2
individually are dispensable in the Myf5-lineage for muscle develop-
ment, for establishing adipocyte precursor pools, and for adipocyte
differentiation, but that AKT2 speciﬁcally is required for lipid ﬁlling
during adipogenesis.
3.4. Most downstream AKT signaling in BAT depends upon AKT2
Next, we examined how Akt loss early in BAT development affects
downstream signaling. By mRNA expression levels, Akt2 is the most
abundant isoform in BAT accounting for 65% of total Akt expression;
Akt1 expresses at about half the levels of Akt2 while Akt3 expresses
nearly 10 and 20-fold less than Akt1 and Akt2, respectively
(Figure 3A). We conﬁrmed ablation of Akt1 and Akt2 in the BAT of
Akt1myf5cKO and Akt2myf5cKO mice using isoform speciﬁc antibodies
(Figure 3B). The residual AKT1 expression likely reﬂects the fact that it
is this most abundant isoform in the non-brown adipocyte population,
which makes up nearly half of the depot [45]. Deleting Akt1 had only a
minor effect on total T-loop (T308) phosphorylation and no effect on
total HM (S473) phosphorylation, as determined with pan-phospho-
speciﬁc antibodies, while, in contrast, deleting Akt2 results in atten-
uation of both (Figure 3B). Interestingly, deleting Akt2 also dramatically
decreases P-AKT-T450 levels, which is a growth-factor insensitive
site, and no effect is observed in the Akt1 knockout (Figure 3B)
consistent with AKT2 being the most abundant isoform in BAT.
Moreover, the AKT substrates P-GSK3b-S9, P-PRAS40-T246, and P-
AS160-T642, and the downstream mTORC1 substrates P-S6K-T389
and P-4EBP1-T37/46, are largely unaffected by deleting Akt1 but
attenuated by deleting Akt2 (Figure 3B). We made similar observations
when comparing Akt1ucp1CreER and Akt2ucp1CreER mice in which Akt1
and Akt2 are deleted only in mature brown adipocytes [46]. Thus,
whether targeting BAT early in development or in mature brown adi-
pocytes, AKT2 is most essential for establishing normal downstream
AKT signaling.
Next, we veriﬁed the effect of AKT2 loss in the rWAT and skeletal
muscles, which are targeted by Myf5-Cre. Consistent with the above
results showing an increase in the number of Myf5-Creneg lineage
adipocytes in the rWAT of Akt2myf5cKO mice, we observe only a small
decrease in total AKT2 protein in whole rWAT lysates (Figure S3C). On
the contrary, lysates of Akt2myf5cKO quadriceps show loss of AKT2 total
protein and the corresponding decrease in P-T308 and P-S473
phosphorylation (Figure S3D) conﬁrming that Myf5-Cre targets skeletal
muscle. However, this has only modest effect on downstream
signaling to P-PRAS40-T246 and little effect if any on P-S6K1-T389 or
4EBP1 laddering (Figure S3D), suggesting tissue-speciﬁc re-
quirements for AKT2 in Myf5-lineages.
3.5. AKT3 does not compensate for AKT1 in BAT development
Although AKT3 is expressed at the lowest level of the three isoforms in
BAT (Figure 3A), other studies have shown that it is functionally
redundant with AKT1, but not AKT2, during thymus, skin, and car-
diovascular and nervous system development [52e54]. To test if AKT3
can compensate for AKT1 in BAT development we generated Akt1-
myf5cKO mice on an Akt3 null background (i.e. Akt3/;Akt1myf5cKO
mice). Both Akt3/ and Akt3/;Akt1myf5cKO mice are indistin-
guishable from control mice with respect to body weight, tissue mass,
and lipid content (Figure 4A,B, Figure S1C, S2C). Western blot
conﬁrmed Akt1 and Akt3 deletion (Figure 4B). We conclude that AKT3
is not compensating for AKT1 in Akt1myf5cKO mice.
3.6. AKT1 and AKT2 exhibit compensatory functions in BAT
development
Although AKT1 loss alone has no obvious phenotype, we wondered if
AKT1 and AKT2 might partially compensate for each other in the Myf5-
Cre lineages as other studies have shown that co-deleting both is more
severe than deleting either isoform alone [55e58]. Indeed, unlike
either single deletion, Akt1/Akt2 myf5cKO (conditional double knockout)
mice are viable but 29% smaller than controls (Figure 5A). Tissue mass
is dramatically decreased by 84% in the iBAT, 66% in sBAT, and 88%
in the rWAT (Figure 5A). The morphology of the few remaining adi-
pocytes in iBAT and rWAT is relatively unaffected (Figure 5B) likely
reﬂecting a Myf5-Cre negative origin. Interestingly, psWAT is propor-
tionally larger in the double knockout, like in the Akt2 single knockout
mice, and contains many hypertrophic adipocytes (Figure 5A,B). The
Figure 3: Most downstream AKT signaling in BAT depends upon AKT2. (A) Total
counts per million (cpm) in BAT of wildtype mice of each akt isoform (Left) (n ¼ 4, one-
way ANOVA). Contribution of each isoform to the total akt levels (Right) (n ¼ 4; no
statistical analysis was used). (B) Western blots of the iBAT of Akt1myf5cKO, Akt2myf5cKO
and respective control littermates (Akt1 ﬂoxed and Akt2 ﬂoxed, respectively) at 6 weeks
old after overnight fasting with or without refeeding for 45 min.
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pgWAT mass is unchanged although there are many smaller than
normal adipocytes; liver mass also increases (Figure 5A,B, Figure S1D,
S2D). Moreover, the mass of the triceps and quadriceps was pro-
portionally normal while only the gastrocnemius muscle is slightly
reduced (Figure S1D). The increased relative kidney mass present in
Akt1myf5cKO is also present in Akt1/Akt2myf5cKO (Figure S1D, S2D).
Western blot analysis on total tissue lysates did not show loss of AKT1
or AKT2 protein in the remaining BAT consistent with the AKT protein
present in total lysates being largely from non-brown adipocytes and
from the few brown adipocytes that did not originate from the Myf5-Cre
precursors (as seen previously when the IR is deleted with Myf5-Cre)
(Figure 5C) [18,21]. In contrast, deletion efﬁciency is high in quadri-
ceps (Figure 5C). These data indicate (1) that AKT1 and AKT2 have
compensatory functions during BAT development, (2) that a threshold
of AKT signaling is required for BAT to develop normally, and (3) that
Myf5-lineage AKT signaling is more essential for adipose tissue
development than skeletal muscle development.
3.7. AKT1 and AKT2 also exhibit compensatory functions in BAT
maintenance
We wondered if a compensatory relationship between Akt1 and Akt2
also exists in mature brown adipocytes. To test this, we generated
ucp1-cre;Akt1;Akt2 mice (i.e. Akt1/Akt2ucp1cKO mice) to doubly delete
Akt1 and Akt2 in mature brown adipocytes. This caused the complete
ablation of all major BAT depots we examined (iBAT, sBAT, cBAT) but
did not affect total body weight or WAT mass and morphology
(Figure 6A,B). Of all the other tissues examined, only the heart
exhibited a slight but signiﬁcant decrease in Akt1/Akt2ucp1cKO mice
(Figure S4A, S5A). Notably, neither adipocyte morphology, nor the
expression of the browning markers ucp1, elovl3, dio2, cpt1b, cidea
Figure 4: AKT3 does not compensate for AKT1 in BAT development. (A) Body weight and fat weights of Akt3/ (n ¼ 9), Akt3/;Akt1myf5cKO (n ¼ 12) and littermate
controls (Akt1 ﬂoxed) (n ¼ 3) at 6 weeks old (one-way ANOVA). (B) Representative H&E images of the indicated fat depots of Akt3/, Akt3/;Akt1myf5cKO and littermate
controls (Akt1 ﬂoxed) at 6 weeks old (n ¼ 3e4). (C) Western blots of the iBAT of Akt3/, Akt3/;Akt1myf5cKO and littermate controls (Akt1 ﬂoxed) at 6 weeks old.
Figure 5: Additional effects of double AKT1/AKT2 deletion in BAT development. (A) Body weight and fat weights of Akt1/2myf5cKO and littermate controls (Akt1/2 ﬂoxed) at 6
weeks old (n ¼ 5, t-test). (B) Representative H&E images of the indicated fat depots of Akt1/2myf5cKO and littermate controls (Akt1/2 ﬂoxed) at 6 weeks old (n ¼ 4). (C) Western
blots of BATs and quadriceps (Quad) of Akt1/2myf5cKO and littermate controls (Akt1/2 ﬂoxed) at 6 weeks old.
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Figure 6: Double AKT1/AKT2 deletion in mature brown adipocytes ablates BAT. (A) Body weight and fat weights of Akt1/2ucp1cKO and littermate controls (Akt1/2 ﬂoxed) at 9
weeks old (n ¼ 9, t-test) (NF, Not Found). (B) Representative H&E images of the indicated fat depots of Akt1/2ucp1cKO and littermate controls (Akt1/2 ﬂoxed) at 9 weeks old (n ¼ 4).
(C) qPCR analysis of the psWAT of Akt1/2ucp1cKO (green squares) and littermate controls (Akt1/2 ﬂoxed, black dots) at 9 weeks old (n ¼ 8, t-test). (D) qPCR analysis of the pgWAT of
Akt1/2ucp1cKO and littermate controls (Akt1/2 ﬂoxed) at 9 weeks old (n ¼ 8, t-test)). (E) Representative images of whole-mount preparations of the indicated fat depots of 9 weeks
old Ucp1-Cre;R26R-mTmG and Akt1/2ucp1cKO;R26R-mTmG mice (n ¼ 3).
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and cox7a change in the psWAT of Akt1/Akt2ucp1cKO mice (Figure 6C).
The WAT-selective markers retn and dpt also do not change
(Figure 6C). Consistently, no asWAT, rWAT, or psWAT adipocytes are
labeled with ucp1-cre when combined with the mTmG reporter
(Figure 6E) and no multi-locular adipocytes are detectable
(Figure 6B,E). Similar results were found in pgWAT (Figure 6B,D and E).
Thus, AKT signaling is also essential for the maintenance of BAT, but
despite the loss of BAT caused by doubly deleting Akt1 and Akt2 in
mature brown adipocytes, widespread "compensatory browning" is
not observed under these conditions.
Because Ucp1-cre is expressed before birth, we also checked if
inducibly deleting Akt1 and Akt2 in the mature adipocytes of older mice
would also result in BAT lipoatrophy. To test this, we generated ucp1-
CreERT2;Akt1;Akt2 mice (Akt1/Akt2ucp1ERcKO) and treated them and
their Cre-negative control littermates with tamoxifen at 6 weeks of age.
Tissues were analyzed at one and three weeks after the ﬁrst tamoxifen
injection. A dramatic decrease in BAT mass was detectable even at one
week post-tamoxifen treatment (more than 60% reduction for iBAT,
50% for sBAT, and 40% for cBAT), which was sustained to at least
three-weeks post treatment (Figure 7A). Total body weight and the
mass of individual non-BAT tissues was unaffected (Figure 7A,B and
Figure S3B). Histological examination reveals a complete lack of BAT
lipid droplets in Akt1/Akt2ucp1ERcKO mice at one-week post-deletion
(Figure 7C) that correlates with reduced UCP1 mRNA and protein
expression (Figure 7D,E). Consistently, Akt1 is reduced and Akt2 ab-
lated at this time point (Figure 7D). Several other brown adipocyte
markers including prdm16, pparg1, pparg2, sgk2, and dio2, and the
white fat marker retn, mRNAs were not negatively affected at this time-
point (Figure 7E) indicating that despite the profound loss of lipid and
reduced UCP1 expression the cells present in the depot retain their
identity as differentiated brown adipocytes. At three-weeks post-
deletion, lipid-ﬁlled brown adipocytes reappear and UCP1 expression
increases to near normal levels and importantly this correlates with the
re-emergence of non-deleted cells (Figure 7CeE). Thus, AKT1 and
AKT2 also exhibit compensatory functions required to maintain BAT in
adult mice.
3.8. Expressing ChREBPb in Akt1/Akt2 double knockout brown
preadipocytes partially rescues differentiation
Finally, we sought to better understand mechanistically how AKT1/2
signaling promotes brown adipocyte differentiation using an in vitro
system. To do this, we generated inducible knockout brown pre-
adipocytes in which the tamoxifen-inducible CreERT2 driver is
expressed in Akt1/Akt2 ﬂoxed brown adipocyte precursor cells in
culture (hereafter Akt1/Akt2iKO cells) [46]. Brieﬂy treating Akt1/Akt2iKO
proliferating precursors with 4-hydroxy tamoxifen (4-OHT) prior to
differentiation efﬁciently ablates both AKT1 and AKT2 compared to
their isogenic (ethanol-treated) brown preadipocyte controls
(Figure S6A). Akt1/Akt2iKO precursors were then induced to differen-
tiate. Western blot using Raptor as a loading control indicates that
Akt1/Akt2iKO brown preadipocytes fail to induce the differentiation
markers PPARg1, PPARg2, ACLY, ACC1/2, FASN, and Perilipin1, C/
EBPa, prdm16, and adiponectin (Figure 8A, S6D). Neutral lipid staining
with Oil Red O conﬁrms that Akt1/Akt2iKO brown preadipocytes cannot
differentiate into lipid accumulating brown adipocytes (Figure 8B).
AKT signaling regulates insulin stimulated glucose uptake; thus, a
defect in glucose uptake may prevent Akt1/Akt2iKO cells from differ-
entiating. To test this, we overexpressed mouse glut1 in Akt1/Akt2iKO
brown preadipocytes which we recently showed increases glucose
uptake in wild type and Akt1 and Akt2 single knockout cells 8-fold [46].
After twelve days of differentiation, glut1 overexpression did not rescue
the expression of ACLY, FASN, or perilipin (Figure S6B) or increase lipid
accumulation (Figure S6C) in Akt1/Akt2iKO cells. Thus, under these
conditions, a defect in glucose uptake does not appear to be the pri-
mary, or only, defect preventing Akt1/Akt2iKO brown preadipocytes
from differentiating.
We recently reported that AKT2 stimulates the activity of the ChREBPa
transcription factor to induce the more potent ChREBPb isoform in
mature brown adipocytes to promote de novo lipogenesis [46]. It has
also been reported that ChREBP might have a role in promoting adi-
pogenesis [59]. Following the differentiation assay, Akt1/Akt2iKO cells
have 50% less chrebpa, consistent with a differentiation defect, and
greater than >95% reduction in chrebpb (Figure S6D). Thus, we next
expressed recombinant ChREBPa or ChREBPb in Akt1/Akt2iKO pre-
cursors and asked whether either ChREBP isoform could rescue dif-
ferentiation. Overexpressing ChREBPa does not rescue any marker of
differentiation (Figure 8A). However, expressing ChREBPb partially
restores PPARg, ACLY, ACC, FASN, and PLIN1 expression (Figure 8A)
and lipid accumulation (Figure 8B) suggesting ChREBPb may be one
AKT effector required for adipogenesis, but that additional factors exist.
To test whether ChREBPb might promote differentiation by driving de
novo lipogenesis, we treated Akt1/Akt2iKO cells expressing either
empty vector or ChREBPb with the FASN inhibitor C75 [60,61], which
blocks adipogenesis [62,63]. Accordingly, C75 (20 mM) blocks the
differentiation of wild type (ethanol treated) cells in a dose dependent
manner using Perilipin as an independent (of the DNL pathway) indi-
cator of differentiation (Figure 8C). Interestingly, ChREBPb over-
expression antagonizes the effect of C75 treatment on ACLY, ACC1/2,
FASN, and Perilipin levels in control cells (Figure 8C). Moreover, the
partial rescue of Akt1/2 knockout cells by ChREBPb overexpression is
not inhibited by C75 treatment (Figure 8C). Thus, inhibiting FASN might
block differentiation by a mechanism indirectly related to its role in
synthesizing palmitate, which can be compensated for by forcing ACLY
and/or ACC1/2 expression, and is positively regulated by AKT2.
4. DISCUSSION
The in vivo roles of the Akt isoforms are incompletely understood.
Until recently, most in vivo studies in adipose tissue relied on whole
body Akt deletion models, for which speciﬁcity is difﬁcult to interpret.
Here, we took advantage of the fact that Myf5-Cre expresses in early
mesenchymal precursors that give rise to brown adipocytes to
investigate the AKT isoforms in BAT development. Because Myf5
precursors also give rise to some white adipocytes and skeletal
muscle, the role of AKT signaling in WAT and skeletal muscle
development was compared. We report that AKT2 is crucial for BAT
growth, speciﬁcally for lipid ﬁlling, but not for expressing differen-
tiation markers. In contrast, AKT1 is dispensable. WAT development
shows similar dependencies. Moreover, AKT1 and AKT2 have partial
overlapping functions because deleting both is more severe that
deleting either isoform individually. In contrast, AKT1 and AKT2 are
dispensable for skeletal muscle development. It should be noted that
Myf5-Cre can target additional lineages, including a few neuronal
lineages in the hypothalamus [64,65] and this could inﬂuence certain
phenotypes. However, the fact that deleting the AKT isoforms in vivo
with Myf5-Cre, Ucp1-Cre, and Ucp1-CrER drivers, or in vitro in brown
preadipocytes with CreER, has similar phenotypes favors the model
that these phenotypes are BAT-speciﬁc. We conclude that AKT
signaling, and in particular AKT2, is uniquely essential for adipose
tissue growth.
Clinical data indicate that excessive visceral fat increases risk of insulin
resistance, while subcutaneous fat accumulation can be protective
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Figure 7: Acutely inducing AKT1/AKT2 deletion triggers rapid turnover of brown adipocytes. (A) Body weight and BAT fat weights of Akt1/2ucp1ERcKO and littermate controls
(Akt1/2 ﬂoxed) 1 or 3 weeks after tamoxifen treatment (1 week post tamoxifen: Akt1/2 ﬂoxed n ¼ 11, Akt1/2ucp1ERcKO n ¼ 10. 3 weeks post tamoxifen: Akt1/2 ﬂoxed n ¼ 8, Akt1/
2ucp1ERcKO n ¼ 10; t-test by time point). (B) WAT fat weights of Akt1/2ucp1ERcKO and littermate controls (Akt1/2 ﬂoxed) 1 or 3 weeks after tamoxifen treatment (1 week post
tamoxifen: Akt1/2 ﬂoxed n ¼ 11, Akt1/2ucp1ERcKO n ¼ 10. 3 weeks post tamoxifen: Akt1/2 ﬂoxed n ¼ 8, Akt1/2ucpERcKO n ¼ 10; t-test by time point). (C) Representative H&E
images of iBAT of Akt1/2ucp1ERcKO and littermate controls (Akt1/2 ﬂoxed) 1 or 3 weeks after tamoxifen treatment (n ¼ 4). (D) Western blots of the iBAT of Akt1/2ucp1ERcKO and
littermate controls (Akt1/2 ﬂoxed) 1 or 3 weeks after tamoxifen treatment. (E) qPCR analysis of the iBAT of Akt1/2ucp1ERcKO and littermate controls (Akt1/2 ﬂoxed) 1 or 3 weeks after
tamoxifen treatment (n ¼ 8; t-test by time point).
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[66e69]. However, the genetic determinants of body fat patterning
remain unknown. Here, we show that deleting Akt2 in the Myf5-
lineage redistributes body fat by reducing the size of Myf5-lineage
depots and enlarging Myf5-lineage negative depots, consistent with
the hypothesis that signaling or metabolic variation between lineages
may affect body fat patterning [18,19,21,30]. Notably, mice studied
here were young (six weeks old) and living in standard conditions (i.e.
22 C and chow diet); further research is needed to understand the
role of adipocyte AKT signaling in adult fat distribution at thermo-
neutrality and on different diets.
Conditional knockouts of AKT1 and/or AKT2 in skeletal muscle or
satellite cells have not previously been described [70] and their skeletal
muscle functions have been largely inferred from transgenic, whole-
body knockout, or small molecule inhibitor studies [71e75]. More-
over, AKT1 rather than AKT2 (the most prevalent isoform in muscle),
has been more extensively studied in muscle likely because AKT1
whole body knockout mice have a whole-body growth defect including
decreased muscle mass [56,57,76]. Data here indicate that AKT1 and
AKT2 are dispensable in the Myf5-Cre lineage for skeletal muscle
development. However, the role of each isoform in muscle metabolic
control remains understudied especially under non-standard laboratory
conditions.
4.1. AKT isoform functions in fat
Previous in vitro studies suggest that AKT1 is required for brown
adipocyte differentiation [30,44,77e79] and whole body Akt1
deletion results in a global growth defect [56,57]. In contrast, we
ﬁnd that deleting Akt1 with Myf5-Cre has no obvious brown or white
adipogenesis, myogenesis, or whole body growth defect in vivo. One
possible reason for the discrepancy regarding brown adipocyte dif-
ferentiation is that in vitro cell culture conditions lack an alternative
mechanism present in vivo that can overcome the AKT1 deﬁciency.
In support, deleting Rictor/mTORC2 with Myf5-Cre shows the same
discrepancy, but the in vitro differentiation defect caused by inhib-
iting mTORC2 can be partially rescued by adding BMP7 to the dif-
ferentiation medium [30]. Another possibility is that AKT2 can
compensate for AKT1 in vivo, but not in vitro. Thus, while AKT1 does
not appear to be required for brown adipocyte differentiation in vivo,
a more detailed biochemical analysis will be required before
concluding that differentiation proceeds by the normal mechanism
when AKT1 is absent.
Whole body Akt2/ mice reportedly have a diabetic phenotype but
normal adipose tissue mass [56,80]. In addition, deleting Akt2 with
PDGFRa-Cre (which targets many cell types including adipocyte pre-
cursors) does not affect normal adipose tissue mass, although HFD-
induced adipose expansion appears to require Akt2 [80].
Finally, in cell culture, deleting Akt2 does not impair adipocyte dif-
ferentiation [30,44,77e79], collectively suggesting that Akt2 regulates
adipose tissue metabolism but not development or growth. However,
another study using a different mouse strain found that Akt2/ mice
have diabetes associated with a decreased whole-body growth deﬁ-
ciency, including decreased adipocyte cell number [81]. Moreover,
Figure 8: AKT signaling drives brown adipocyte differentiation in part by stimulating ChREBPb expression. (A) Western blot analysis of differentiated Akt1/Akt2iKO-cells
treated with 4-OHT before differentiation overexpressing plasmids containing ChREBP isoforms (pMSCV-Cha and pMSCV-Chb). (B) Oil Red O staining of differentiated Akt1/Akt2iKO-
cells treated with 4-OHT before differentiation overexpressing plasmids containing ChREBP isoforms (pMSCV-Cha and pMSCV-Chb). (C) Western blot analysis of differentiated
Akt1/Akt2iKO-cells treated with 4-OHT before differentiation overexpressing plasmids containing pMSCV-Chb treated with vehicle (DMSO) o C75 at the indicated doses starting at
day 8 of differentiation.
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adiponectin-cre;akt2 mice (C57BL6/J) have less adipose tissue mass
due in part to reduced adipocyte size [46]. In addition, Akt2ucp1ERcKO
mice (C57BL6/J) have reduced BAT mass due to depleted lipid storage
[46], and here, we show that deleting akt2 with Myf5-cre reduces both
BAT and WAT mass without affecting differentiation markers. Taken
together, these data argue that, with some strain and/or lineage
dependent variation, adipocytes require AKT2 to accumulate lipids,
which may be due in part to its role in controlling glucose uptake and
de novo lipogenesis (DNL) enzyme expression. Notably, familiar partial
lipodystrophy is associated with Akt2 mutations in humans [82] indi-
cating AKT2’s role in regulating fat mass is conserved.
Doubly deleting Akt1 and Akt2 with Myf5-cre, Ucp1-cre, or Ucp1-
creER, results in severe BAT lipoatrophy in vivo suggesting that
AKT1 and AKT2 have some partial overlapping functions. This is
consistent with recent studies showing that adiponectin-cre;Ak-
t1;Akt2 mice have severe lipodystrophy while adiponectin-cre;Akt2
mice have only moderately less fat [46,58]. Surprisingly, skeletal
muscle mass in Akt1/Akt2 myf5cKO mice is mostly normal (this study)
and loss of Akt1/Akt2 in hepatocytes does not ablate them [83], and
while global Akt1/;Akt2/ deletion causes a severe growth
deﬁciency, many tissues develop as some viable Akt1/;Akt2/
mice are born (though they die shortly after) [55]. One note regarding
our tamoxifen-inducible double knockout model; it has been shown
that tamoxifen administration alone can cause transient lipoatrophy
in mice, and additionally can synergize with certain adipocyte-
speciﬁc gene deletions to cause a synthetic lethal like phenotype
in adipose tissue [47e49]. Though we did not observe obvious lip-
oatrophy in tamoxifen-treated control mice at the time points
examined, we cannot rule out that there is a synergy between
tamoxifen and Akt1/Akt2 loss in the double knockout. Nevertheless,
the conditional targeting of AKT in adipocytes using an assortment of
Cre drivers indicates a uniquely essential function for AKT in adipose
tissue growth and likely its maintenance. Sorting out the overlapping
and distinct in vivo functions of each AKT isoform remains an
important and challenging goal.
4.2. The mTOR complexes, AKT and ChREBP
Conventional models place mTORC2 upstream of all AKT functions.
However, this view is oversimpliﬁed given the fact that doubly deleting
akt1 and akt2 in brown or white fat is far more severe than deleting the
essential mTORC2 subunit Rictor (this study) [30,32,58]. Moreover,
downstream AKT substrate phosphorylation is largely normal in Rictor-
deﬁcient adipocytes [30,32]. Yet, there is phenotypic similarity be-
tween Rictormyf5cKO and Akt2myf5cKO mice (which is also apparent when
comparing RictoradipoqcKO and Akt2adipoqcKO mice) as both BAT
knockouts have reduced Chrebpb, DNL gene expression, and lipid
content [32,46]. One possibility is that an unidentiﬁed AKT pathway
linked to DNL may be uniquely dependent upon mTORC2 in adipocytes.
Alternatively, mTORC2 and AKT2 loss could converge on DNL and lipid
regulation through different mechanisms. Resolving the acute and
prolonged effects of mTORC2 loss is important because AKT hydro-
phobic motif phosphorylation by mTORC2 is a major biomarker of
cellular insulin resistance.
Conventional models also place mTORC1 downstream of AKT because
AKT can phosphorylate and inhibit TSC2 and PRAS40, both of which
negatively regulate mTORC1. Consistently, deleting AKT2 with Myf5-Cre
impairs mTORC1 signaling in BAT. However, deleting the essential
mTORC1 subunitRaptorwithMyf5-Cre results in a severe developmental
defect and late embryonic lethality [30] suggesting a broader require-
ment for mTORC1 in Myf5 lineages. Interestingly, congenitally deleting
Raptor with Adiponectin-Cre or Ucp1-Cre reduces WAT and BAT tissue
mass, respectively, but not as severely as deleting Akt1/Akt2 [46,84].
Moreover, AKT2 loss impairs de novo lipogenesis gene expression, while
Raptor loss increases de novo lipogenesis gene expression, likely by
relieving negative feedback inhibition on AKT signaling [46,84]. Thus,
there are complex relationships between themTOR complexes, AKT, and
metabolism, and our suspicion is that conventional models do not yet
depict important pathway, cell, or tissue-speciﬁc idiosyncrasies.
The downstream transcriptional targets of AKT action in adipocytes
have not been fully deﬁned. In mature brown adipocytes, AKT2 pro-
motes Chrebpb expression and do novo lipogenesis [46]. Data here
and elsewhere also identify ChREBP as a candidate AKT effector in
adipocyte differentiation, although other factors are likely involved [59].
One of the other factors could be SREBP [85,86]. Chrebp whole-body
knockout mice show reduced total adiposity [87], consistent with a role
for CHREBP in fat growth. However, adipocyte-speciﬁc Chrebp deletion
has only minor effects on fat mass but reduces glucose uptake and
causes insulin resistance [88]. Thus, AKT may regulate glucose
transport and insulin sensitivity at least in part through ChREBP, but it
may regulate adipocyte cell size through other pathways, such as lipid
uptake, TAG synthesis, lipolysis and/or thermogenesis [32,46,89,90].
A BAT-speciﬁc ChREBP knockout model has not yet been reported. The
continued elucidation of how mTORC2 and AKT signaling control
ChREBP activity is essential to fully understanding the mechanisms of
adipose tissue growth and insulin resistance.
5. CONCLUSIONS
Resolving the tissue-speciﬁc biochemical functions of AKT signaling in
development and metabolism is important to understanding many
human diseases. Using mouse genetics, we deﬁne distinct and
overlapping functions for AKT1 and AKT2 in brown and white adipose
tissue development and show that they are largely dispensable for
skeletal muscle development. These ﬁndings are particularly relevant
to understanding the pathogenesis and prevention of obesity and in-
sulin resistance; thus, future experiments aimed at deciphering the
critical AKT targets in fat growth are warranted.
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